Source comparison
Melanotan-1 vs Melanotan-2 — The Safety Profile Difference
Melanotan-2 (MT-2) is a synthetic analog derived from the same -MSH precursor as MT-1 but with a critical structural difference: MT-2 is a cyclic heptapeptide that binds non-selectively to multiple melanocortin receptors. MC1R, MC3R, MC4R, and MC5R. Rather th
This comparison does not assign a generated winner or score.
- Melanotan-2 (MT-2) is a synthetic analog derived from the same α-MSH precursor as MT-1 but with a critical structural difference: MT-2 is a cyclic heptapeptide that binds non-selectively to multiple melanocortin receptors. MC1R, MC3R, MC4R, and MC5R. Rather than targeting MC1R alone. This broader receptor activity introduces side effects absent in MT-1, including nausea (reported in 40–60% of users in early trials), spontaneous erections in males (due to MC4R activation in the hypothalamus), and appetite suppression (MC4R's role in satiety regulation).
- Melanotan-1's selectivity for MC1R limits its activity to melanocytes, avoiding the central nervous system effects that make MT-2 problematic. A 2006 study published in the Journal of Clinical Endocrinology & Metabolism comparing afamelanotide (MT-1) to bremelanotide (a derivative related to MT-2) found that afamelanotide produced zero incidence of nausea or CNS-mediated side effects at therapeutic doses, while bremelanotide's non-selective binding caused dose-limiting nausea in 58% of participants.
- The practical implication: MT-1's tanning effect develops more gradually (10–14 days to visible pigmentation vs 3–5 days for MT-2) but without the gastrointestinal distress, blood pressure fluctuations, or sexual side effects associated with broader melanocortin activation. For individuals prioritizing photoprotection over rapid cosmetic bronzing, MT-1's safety profile makes it the more sustainable option. Though both remain investigational compounds outside their specific FDA-approved indications.